Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday? Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and congenital hyperinsulinism.
AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024 AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
